Shanghai Shiguibao Pharmaceutical

Sino-American Shanghai Squibb Pharmaceuticals (SASS) is a landmark joint venture established in 1982 between Bristol Myers Squibb (BMS) and Chinese partners, including Shanghai Pharmaceuticals Holding and Sinopharm. As the first Sino-American pharmaceutical joint venture in China, SASS has played a pivotal role in introducing modern medicine to the Chinese market. The company manufactures and commercializes a broad portfolio of BMS products, spanning therapeutic areas such as cardiovascular health, metabolism, oncology, and immunology. Key marketed products include metformin for diabetes, entecavir for hepatitis B, and various cardiovascular agents. Under BMS's "China 2030 Strategy," SASS is increasingly focused on bringing innovative biologics and advanced therapies, such as CAR-T cell treatments, to Chinese patients. The company operates a large-scale manufacturing facility in Shanghai and continues to be a key vehicle for BMS's expansion in the region.